• Home
  •  
    Regions
    • Europe
    • UK & Ireland
    • DACH
    • Nordic
    • France
    • Southern Europe
    • Benelux
    • CEE
    • Asia
  •  
    Deals
    • Buyouts
    • Venture
    • Exits
    • Refinancings
    • Build-up
    • Turnaround
    • Secondaries
    • Advanced deal search
  •  
    Funds
    • Buyout
    • Venture
    • Mezzanine
    • Debt
    • Funds-of-funds
    • Secondaries
    • Fundraising pipelines
    • Advanced funds search
  •  
    GPs & LPs
    • GP profiles
    • LP profiles
    • GP news
    • LP news
    • Sponsors search
    • LPs search
  •  
    Secondaries
    • Deals
    • Funds
    • News
    • Analysis
  •  
    People
    • People moves
    • Analysis
    • In Profile
    • Q&A
    • Videos
    • Comment
  •  
    Analysis
    • In Profile
    • Fundraising
    • Q&A
    • Comment
    • Videos
    • Podcast
    • Reports
    • Data Snapshots
  •  
    Unquote Data
    • Deals search
    • Exits search
    • Funds search
    • Sponsors search
    • Advisers search
    • LPs search
    • League tables
    • Reports
  • Sign in
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)203 741 1137

      Email: Georgina.Lawson@acuris.com

      • Sign in
     
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
  • Free Trial
  • Subscribe
Unquote
Unquote
  • Home
  • Regions
  • Deals
  • Funds
  • GPs & LPs
  • Secondaries
  • People
  • Analysis
  • Unquote Data
      • Deals search
      • Exits search
      • Funds search
      • Sponsors search
      • Advisers search
      • LPs search
      • League tables
      • Reports
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)203 741 1137

    Email: Georgina.Lawson@acuris.com

    • Sign in
 
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 
UNQUOTE
  • Exits

Maven makes 9x on Regent Pacific/Plethora exit

  • Mikkel Stern-Peltz
  • Mikkel Stern-Peltz
  • 12 December 2016
  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  

Scottish GP Maven Capital Partners has made 9x money on its investment in London-based premature-ejaculation-focused pharmaceuticals company Regent Pacific, after a full exit.

The exit saw the buyout firm liquidate its shareholding in Regent Pacific – formerly known as Plethora Solutions – which is listed on the Hong Kong Stock Exchange.

The sale will return cash to the Capital for Enterprise Fund A, a £35m vehicle managed by Maven and launched by Capital for Enterprise (now British Business Bank) as part of a scheme in 2009 to invest in British SMEs. The fund made 17 investments over a 12-month period, according to a statement by Maven.

For Maven, the exit comes six years after it first backed Regent Pacific with a mezzanine loan. In the following years, the GP consolidated its holding in the company through increased equity warrants as Regent Pacific grew.

Hong Kong-based biopharma-focused holding vehicle Regent Pacific acquired Plethora for $157m in March 2016, delisting the company from London's AIM exchange. The holding vehicle made its initial approach in November 2015 with an offer of 12.5 pence per share for existing shareholders, having itself built up a stake of around 30% in the business.

According to the offer document, Plethora expected "significant negative impact" in January 2016 if it did not raise additional capital, due to the company running a loss of around £493,000 in the six months to 30 June 2015, at a time when its cash balance was £2.8m.

Previous funding
Through the Capital for Enterprise Fund A, Maven provided a £1m mezzanine loan facility to Plethora in July 2010.

Company
Headquartered in London, Plethora is a pharmaceuticals company that produces a treatment for male premature ejaculation.

The company acquires, develops and markets products for the treatment and management of urological disorders, with a particular focus on the male sexual health market.

Founded in 2003, the company posted a loss of £4.329m for the year ending 31 December 2015, according to its own financial filings.

People
Maven Capital Partners – Stella Panu (partner).

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  
  • Topics
  • Exits
  • Healthcare
  • UK / Ireland
  • Maven Capital Partners
  • United Kingdom
  • Pharmaceuticals

More on Exits

Partners Group to release IMs for Civica sale in mid-September
Partners Group to release IMs for Civica sale in mid-September

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • Exits
  • 04 September 2023
Actera Group explores strategic options for Celebi Ground Handling
Actera Group explores strategic options for Celebi Ground Handling

Several investors placed bids for the company in 2022 but mismatch in pricing didn't lead to a deal

  • Exits
  • 30 August 2023
Norstat owner Triton Partners explores sale via William Blair
Norstat owner Triton Partners explores sale via William Blair

GP has owned the Norway-headquarterd market research business for almost four years

  • Exits
  • 25 August 2023
IK Investment-backed Eres expected to hit the auction block by 2024
IK Investment-backed Eres expected to hit the auction block by 2024

French employee savings distribution and management firm could be valued at a few hundred million euros

  • Exits
  • 24 August 2023

Latest News

Partners Group to release IMs for Civica sale in mid-September
  • Exits
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • 04 September 2023
BHM Group builds on PE strategy, eyes European medtech and renewable energy acquisitions
  • Investments
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Czech Republic-headquartered family office is targeting DACH and CEE region deals

  • 01 September 2023
Redalpine expands leadership team amid CHF 1bn-plus fundraise
  • Venture
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO

  • 31 August 2023
Change Ventures aims to hold final close for EUR 20m third fund by mid-2024
  • Funds
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds

  • 31 August 2023
Back to Top
  • About Unquote
  • Advertise
  • Contacts
  • About Acuris
  • Terms of Use
  • Privacy Policy
  • Group Disclaimer
  • Twitter
  • LinkedIn

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013